Stocks in the FTSE 100 pharma firm, Shire, dropped sharply on Monday morning after it announced a rival had been given permission to make a generic version of its blockbuster treatment for Attention Deficit Hyperactivity Disorder (ADHD), Adderall XR.
Swiss firm Actavis has been given the all clear by the US Food and Drug Administration to manufacture a generic form of Adderall, which analysts at Nomura estimate is worth around 10% of Shire's total earnings per share.
Little wonder, then, that shortly after the open Shire shares had dropped 10.4%
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
In announcing the news Shire admitted "there will be multiple dynamics affecting the overall market following the approval of the Actavis generic".
But the British company maintained it would "...deliver good, full-year 2012 earnings growth."
Nomura still rates Shire as a buy because 40% of its sales are exposed to the US ADHD market which grew at 9% over the last five years.
BS
-
How to find the best luxury hotel dealsKnowing how to find the best luxury hotel deals can help holidaymakers enjoy high-end experiences without the sky-high costs. We reveal how to bag the best value for less.
-
Frozen thresholds could push ‘tax freedom day’ to latest date this centuryTax freedom day is the point in the year you stop earning for the taxman and start earning for yourself. A rising tax burden could push it to 12 June this year – the latest date since 1982.
